Growth Hormone Secretagogues: A Research Overview
An introduction to the class of peptides known as growth hormone secretagogues (GHSs), how they interact with the GHS receptor, and what the current research literature says about their studied mechanisms.
Growth hormone secretagogues (GHSs) are a class of peptides and small molecules that have been studied for their interaction with the growth hormone secretagogue receptor (GHS-R), also known as the ghrelin receptor. Research has examined whether compounds in this class may influence the pulsatile release of growth hormone from the pituitary gland.
The GHS-R Receptor
The GHS-R was identified before its endogenous ligand was discovered. Researchers working with synthetic GHSs in the 1980s and 1990s observed that these compounds appeared to act on a receptor distinct from the growth hormone-releasing hormone (GHRH) receptor. The endogenous ligand for this receptor was later identified as ghrelin, a 28-amino-acid peptide primarily produced in the stomach.
Understanding the receptor's location and distribution matters for evaluating research claims. GHS-R1a (the active isoform) is expressed in the pituitary, hypothalamus, hippocampus, heart, and several peripheral tissues. This distribution means that compounds interacting with this receptor may affect multiple systems, which is relevant when evaluating study outcomes.
How GHSs May Interact with GH Release
Research on GHSs suggests they may influence GH release through at least two complementary mechanisms:
Direct pituitary stimulation: Some studies have found that GHSs may act directly on pituitary somatotrophs, the cells responsible for producing and releasing growth hormone.
Hypothalamic modulation: Other research suggests GHSs may stimulate GHRH release from the hypothalamus, indirectly amplifying the GH pulse.
Somatostatin suppression: Some animal studies have suggested GHSs may reduce somatostatin tone, the inhibitory signal that counteracts GHRH. This would, in theory, allow for larger GH pulses, though the significance of this mechanism in humans remains an active area of study.
These mechanisms are not mutually exclusive, and researchers have proposed that GHSs may work synergistically with endogenous GHRH.
Classification of GHSs
GHSs used in research can be broadly classified:
| Category | Examples | Key Characteristic |
|---|---|---|
| Peptide GHSs | GHRP-2, GHRP-6, Hexarelin, Ipamorelin | Mimic ghrelin at the receptor |
| Non-peptide GHSs | MK-0677 (Ibutamoren) | Orally active small molecules |
| GHRH analogs | CJC-1295, Sermorelin | Act on GHRH-R, not GHS-R |
| Modified ghrelin | Various research compounds | Ghrelin fragments or analogs |
Note that GHRH analogs like CJC-1295 act through a different receptor (GHRH-R) and are technically not GHSs, though they are often grouped in the same research literature due to their related downstream effects.
Selectivity: Why It Matters for Research
Researchers have paid particular attention to receptor selectivity within this class. Some peptides in this category — particularly GHRP-6 and GHRP-2 — have been observed in animal and some human studies to also interact with other receptors, potentially affecting hunger signaling (via ghrelin's role in appetite) and prolactin or cortisol release.
Ipamorelin has been highlighted in the literature for its apparent greater selectivity for the GHS-R compared to GHRP-2 and GHRP-6 in vitro, with some animal studies suggesting less pronounced off-target effects. Whether this selectivity difference is clinically meaningful in human studies remains to be established.
Current Research Status
GHSs have been investigated in a range of clinical contexts, including:
- Growth hormone deficiency states
- Aging-related GH decline (somatopause)
- Muscle wasting conditions (cachexia)
- Post-surgical recovery
Several compounds in this class have progressed to clinical trials, though none have received widespread regulatory approval as of this writing. Sermorelin (a GHRH analog) has been approved in some jurisdictions as a diagnostic agent and for pediatric GH deficiency; the broader GHS class remains largely in research status.
Researchers interested in GH biology should note that GH secretion is highly pulsatile and variable, which creates significant methodological challenges for study design. The timing, frequency, and amplitude of GH pulses affect downstream IGF-1 production, and different GHS compounds may alter these parameters differently.
Key Limitations in the Literature
The GHS research literature has several limitations worth noting:
- Many studies use supraphysiological doses relative to natural ghrelin activity
- Short-term changes in GH pulse do not necessarily predict sustained IGF-1 changes
- Most long-term data comes from pharmaceutical GHSs in specific patient populations, not healthy subjects
- Individual response to GHS compounds is highly variable and age-dependent
For researchers evaluating claims about specific GHS peptides, these limitations are the appropriate context for interpreting any single study's findings.
References
- 1.Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LH. “A receptor in pituitary and hypothalamus that functions in growth hormone release.” Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974 [PubMed]
- 2.Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. “Ghrelin is a growth-hormone-releasing acylated peptide from stomach.” Nature. 1999;402(6762):656-660. doi:10.1038/45230 [PubMed]
- 3.Bowers CY. “GH releasing peptides — structure and kinetics.” Journal of Pediatric Endocrinology. 1993;6(1):21-31 [PubMed]